A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)

Satoshi Watanabe, Naoki Furuya, Atsushi Nakamura, Jun Shiihara, Ichiro Nakachi, Hisashi Tanaka, Mika Nakao, Koichi Minato, Masahiro Seike, Shinichi Sasaki, Akira Kisohara, Susumu Takeuchi, Ryoichi Honda, Kei Takamura, Hiroshi Kagamu, Kenichi Yoshimura, Kunihiko Kobayashi, Toshiaki Kikuchi